Search - tctmd.com

Displaying 781 - 800 of 1949

Sort: Relevancy | Date

Presentation TCT 2016

Radiation Exposure and Protection

Presenter: Charles E. Chambers, Stephen Balter

November 01, 2016

News Conference News TCT 2016

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

Todd Neale

November 01, 2016

Presentation TCT 2016

Direct Flow: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Azeem Latib

November 01, 2016

Presentation TCT 2016

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Stephen G. Ellis

November 01, 2016

News Industry News TCT 2016

Long-Term Study Results Show that PFO Closure is More Effective Than Medical Management in Preventing Recurrent Stroke

November 01, 2016

News Industry News TCT 2016

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

November 01, 2016

Presentation TCT 2016

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Presenter: Nicole Ibrahim, Martin B. Leon, Jaime Raben

November 01, 2016

Presentation TCT 2016

Lotus and EDGE: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Ted Feldman

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Robert-Jan van Geuns

November 01, 2016

Presentation TCT 2016

Portico: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Raj Makkar

November 01, 2016

Presentation TCT 2016

Bare Metal and 1st Generation Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Dmitriy N. Feldman, Emmanouil S. Brilakis

November 01, 2016

Presentation TCT 2016

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Presenter: Michael C. John, Gregg W. Stone, Jason R. Weidman

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: Polymer-free DES - LEADERS-free 2-year and RevElution

Presenter: Philip M. Urban, Stephen G. Worthley, Christian M. Spaulding

November 01, 2016

Presentation TCT 2016

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

Presenter: Michael C. John, Gregg W. Stone, Chuck Simonton

November 01, 2016

Presentation TCT 2016

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Jeffrey J. Popma

November 01, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

Presenter: Philip M. Urban, Stephen G. Worthley, Sigmund Silber

November 01, 2016

Presentation TCT 2016

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Presenter: Michael C. John, Gregg W. Stone, P.F. Adrian Magee

November 01, 2016

Presentation TCT 2016

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., John G. Webb

November 01, 2016

Presentation TCT 2016

Complications Related to Contrast and Commonly Used Medications

Presenter: Giora Weisz, Payam Dehghani

November 01, 2016

Advertisement

Radiation Exposure and Protection

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

Direct Flow: Design Features, Special Attributes, and Clinical Trial Program

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Long-Term Study Results Show that PFO Closure is More Effective Than Medical Management in Preventing Recurrent Stroke

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Lotus and EDGE: Design Features, Special Attributes, and Clinical Trial Program

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Portico: Design Features, Special Attributes, and Clinical Trial Program

Bare Metal and 1st Generation Drug-Eluting Stents: Devices, Indications, and Outcomes

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Highlights (And my Interpretations) From: Polymer-free DES - LEADERS-free 2-year and RevElution

Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

FDA Perspectives on Short DAPT IDE Trials

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Complications Related to Contrast and Commonly Used Medications

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content